{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:19:18Z","timestamp":1790936358584,"version":"4.1.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytotoxic T-lymphocyte (CTL) responses can be generated against peptides derived from the immunoglobulin (Ig) V region in some but not all patients. The main reason for this appears to be the low peptide-binding affinity of Ig-derived peptides to major histocompatibility complex (MHC) class I molecules and their resulting low immunogenicity. This might be improved by conservative amino acid modifications at the MHC-binding residues of the peptides (heteroclitic peptides). In this study, it was found that in 18 Ig-derived peptides, that heteroclitic peptides from the Ig gene with improved binding to human leukocyte antigen (HLA)-A*0201 can be used to improve CTL responses. Amino acid substitution substantially increased predicted binding affinity, and there was a strong correlation between predicted and actual binding to HLA-A*0201. CTLs generated against the heteroclitic peptide had not only enhanced cytotoxicity against the heteroclitic peptide but also increased killing of antigen-presenting cells pulsed with the native peptide. Surprisingly, no difference was observed in the frequency of T cells detected by MHC class I peptide tetramers after stimulation with the heteroclitic peptide compared with the native peptide. CTLs generated against heteroclitic peptides could kill patients' tumor cells, showing that Ig-derived peptides can be presented by the tumor cell and that the failure to mount an immune response (among other reasons) likely results from the low immunogenicity of the native Ig-derived peptide. These results suggest that heteroclitic Ig-derived peptides can enhance immunogenicity, thereby eliciting immune responses, and that they might be useful tools for enhancing immunotherapy approaches to treating B-cell malignant diseases.<\/jats:p>","DOI":"10.1182\/blood.v98.10.2999","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"2999-3005","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Induction of cytotoxic T-cell responses against immunoglobulin V region\u2013derived peptides modified at human leukocyte antigen\u2013A2 binding residues"],"prefix":"10.1182","volume":"98","author":[{"given":"Sabine","family":"Harig","sequence":"first","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M.","family":"Krackhardt","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Trojan","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Barrett","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Broderick","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jason","family":"Zauls","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[{"name":"From the Department of Adult Oncology, Dana-Farber Cancer Institute; and the Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021218504196600_B1","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1073\/pnas.72.6.2357","article-title":"Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes.","volume":"72","author":"Janeway","year":"1975","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218504196600_B2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/eji.1830161110","article-title":"Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules.","volume":"16","author":"Bogen","year":"1986","journal-title":"Eur J Immunol."},{"key":"2020021218504196600_B3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.139.8.2825","article-title":"Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.","volume":"139","author":"Campbell","year":"1987","journal-title":"J Immunol."},{"key":"2020021218504196600_B4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4049\/jimmunol.138.2.628","article-title":"Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.","volume":"138","author":"George","year":"1987","journal-title":"J Immunol."},{"key":"2020021218504196600_B5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-3083.1993.tb01668.x","article-title":"Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo.","volume":"37","author":"Lauritzsen","year":"1993","journal-title":"Scand J Immunol."},{"key":"2020021218504196600_B6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/nm0996-1038","article-title":"DNA immunization induces protective immunity against B-cell lymphoma.","volume":"2","author":"Syrengelas","year":"1996","journal-title":"Nat Med."},{"key":"2020021218504196600_B7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/3266","article-title":"DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma.","volume":"4","author":"King","year":"1998","journal-title":"Nat Med."},{"key":"2020021218504196600_B8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/intimm\/12.5.691","article-title":"Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens.","volume":"12","author":"Tani","year":"2000","journal-title":"Int Immunol."},{"key":"2020021218504196600_B9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJM199210223271705","article-title":"Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.","volume":"327","author":"Kwak","year":"1992","journal-title":"N Engl J Med."},{"key":"2020021218504196600_B10","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial.","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood."},{"key":"2020021218504196600_B11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/eji.1830270435","article-title":"T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma.","volume":"27","author":"Wen","year":"1997","journal-title":"Eur J Immunol."},{"key":"2020021218504196600_B12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2141.1998.00592.x","article-title":"Immunogenicity and cross-reactivity with idiotypic IgA of VH CDR3 peptide in multiple myeloma.","volume":"100","author":"Wen","year":"1998","journal-title":"Br J Haematol."},{"key":"2020021218504196600_B13","first-page":"957","article-title":"Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma.","volume":"4","author":"Wen","year":"1998","journal-title":"Clin Cancer Res."},{"key":"2020021218504196600_B14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<671::AID-IJC7>3.0.CO;2-E","article-title":"T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.","volume":"80","author":"Fagerberg","year":"1999","journal-title":"Int J Cancer."},{"key":"2020021218504196600_B15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med."},{"key":"2020021218504196600_B16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1182\/blood.V95.4.1342.004k19_1342_1349","article-title":"Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells.","volume":"95","author":"Osterroth","year":"2000","journal-title":"Blood."},{"key":"2020021218504196600_B17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/76243","article-title":"Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.","volume":"6","author":"Trojan","year":"2000","journal-title":"Nat Med."},{"key":"2020021218504196600_B18","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1182\/blood.V97.6.1750","article-title":"Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells.","volume":"97","author":"Wen","year":"2001","journal-title":"Blood."},{"key":"2020021218504196600_B19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science."},{"key":"2020021218504196600_B20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1084\/jem.176.5.1453","article-title":"A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.","volume":"176","author":"Traversari","year":"1992","journal-title":"J Exp Med."},{"key":"2020021218504196600_B21","doi-asserted-by":"crossref","first-page":"9730","DOI":"10.1073\/pnas.93.18.9730","article-title":"The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.","volume":"93","author":"Huang","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218504196600_B22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0952-7915(96)80081-1","article-title":"Peptide-based cancer vaccines.","volume":"8","author":"Melief","year":"1996","journal-title":"Curr Opin Immunol."},{"key":"2020021218504196600_B23","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/nm1195-1179","article-title":"Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides.","volume":"1","author":"Mandelboim","year":"1995","journal-title":"Nat Med."},{"key":"2020021218504196600_B24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1073\/pnas.88.3.991","article-title":"Peptide-induced antiviral protection by cytotoxic T cells.","volume":"88","author":"Schulz","year":"1991","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2020021218504196600_B25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.2910630622","article-title":"Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3 [letter].","volume":"63","author":"Marchand","year":"1995","journal-title":"Int J Cancer."},{"key":"2020021218504196600_B26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/(SICI)1097-0215(19960410)66:2<162::AID-IJC4>3.0.CO;2-0","article-title":"Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.","volume":"66","author":"Jaeger","year":"1996","journal-title":"Int J Cancer."},{"key":"2020021218504196600_B27","first-page":"2479","article-title":"Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.","volume":"56","author":"Hu","year":"1996","journal-title":"Cancer Res."},{"key":"2020021218504196600_B28","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.4049\/jimmunol.149.11.3580","article-title":"Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2.","volume":"149","author":"Parker","year":"1992","journal-title":"J Immunol."},{"key":"2020021218504196600_B29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.152.1.163","article-title":"Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains.","volume":"152","author":"Parker","year":"1994","journal-title":"J Immunol."},{"key":"2020021218504196600_B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.iy.11.040193.001241","article-title":"Peptides naturally presented by MHC class I molecules.","volume":"11","author":"Rammensee","year":"1993","journal-title":"Annu Rev Immunol."},{"key":"2020021218504196600_B31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF00172063","article-title":"MHC ligands and peptide motifs: first listing.","volume":"41","author":"Rammensee","year":"1995","journal-title":"Immunogenetics."},{"key":"2020021218504196600_B32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s002510050595","article-title":"SYFPEITHI: database for MHC ligands and peptide motifs.","volume":"50","author":"Rammensee","year":"1999","journal-title":"Immunogenetics."},{"key":"2020021218504196600_B33","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.","volume":"153","author":"Sette","year":"1994","journal-title":"J Immunol."},{"key":"2020021218504196600_B34","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.4049\/jimmunol.156.9.3308","article-title":"Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.","volume":"156","author":"Van der Burg","year":"1996","journal-title":"J Immunol."},{"key":"2020021218504196600_B35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1074-7613(00)80048-5","article-title":"A kinetic basis for T cell receptor repertoire selection during an immune response.","volume":"10","author":"Savage","year":"1999","journal-title":"Immunity."},{"key":"2020021218504196600_B36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/eji.1830230603","article-title":"Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes.","volume":"23","author":"Nijman","year":"1993","journal-title":"Eur J Immunol."},{"key":"2020021218504196600_B37","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","article-title":"Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.","volume":"88","author":"Molldrem","year":"1996","journal-title":"Blood."},{"key":"2020021218504196600_B38","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1074-7613(00)80066-7","article-title":"The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes.","volume":"10","author":"Vonderheide","year":"1999","journal-title":"Immunity."},{"key":"2020021218504196600_B39","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.4049\/jimmunol.147.4.1392","article-title":"A single amino acid substitution in an MHC class I molecule allows heteroclitic recognition by lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes.","volume":"147","author":"Muller","year":"1991","journal-title":"J Immunol."},{"key":"2020021218504196600_B40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1084\/jem.188.9.1553","article-title":"Heteroclitic immunization induces tumor immunity.","volume":"188","author":"Dyall","year":"1998","journal-title":"J Exp Med."},{"key":"2020021218504196600_B41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med."},{"key":"2020021218504196600_B42","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI119822","article-title":"CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.","volume":"100","author":"Schultze","year":"1997","journal-title":"J Clin Invest."},{"key":"2020021218504196600_B43","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood."},{"key":"2020021218504196600_B44","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol."},{"key":"2020021218504196600_B45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1126\/science.1546328","article-title":"Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.","volume":"255","author":"Hunt","year":"1992","journal-title":"Science."},{"key":"2020021218504196600_B46","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.4049\/jimmunol.159.5.2391","article-title":"Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination.","volume":"159","author":"Tourdot","year":"1997","journal-title":"J Immunol."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2999\/1678489\/h8220102999.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2999\/1678489\/h8220102999.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T20:11:56Z","timestamp":1682280716000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/10\/2999\/53022\/Induction-of-cytotoxic-Tcell-responses-against"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,15]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.10.2999","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,15]]}}}